Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature

doi:10.12998/wjcc.v10.i8.2569

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 8

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3770)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series.

Item

Count

PDF

286

WORD

110

HTML

2333

Figures (1-2)

233

Sum=2962

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

263

Download

544

Sum=807

Mar 16, 2022 (publication date) through May 26, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Cases. Mar 16, 2022; 10(8): 2569-2576
Published online Mar 16, 2022. doi: 10.12998/wjcc.v10.i8.2569

Full Size Figure Download Figure

Figure 2 Timeline of events. MS: Multiple sclerosis; MDT: Multidisciplinary Team; MRE: Magnetic resonance enterography.

Citation: Au M, Mitrev N, Leong RW, Kariyawasam V. Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature. World J Clin Cases 2022; 10(8): 2569-2576
URL: https://www.wjgnet.com/2307-8960/full/v10/i8/2569.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i8.2569